Laurie Jones
Adult Health · Charleston, WVNPI 1073737714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novartis at 32.9% of the total.
Across 63 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$479
- Regeneron Healthcare Solutions, Inc.$314
- Takeda Pharmaceuticals U.S.A., Inc.$238
- Optinose US, Inc.$99
- AbbVie$54
- Pharming Healthcare, Inc.$33
- plus $242 from 12 others
What the payments were for
- Food & beverage$1,459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $479 |
| Regeneron Healthcare Solutions, Inc. | 12 | $314 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $238 |
| Optinose US, Inc. | 5 | $99 |
| AbbVie | 3 | $54 |
| Pharming Healthcare, Inc. | 2 | $33 |
| Bio Products Laboratory USA, Inc. | 2 | $32 |
| Abbott | 2 | $25 |
| Alk-abello, Inc | 1 | $23 |
| AstraZeneca | 1 | $21 |
| Alkermes, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Kaleo, Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| CSL Behring | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
How this compares
$1,459 in reported general payments places this provider in the 80th percentile of 30 adult health providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $21,671 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $1,265 |
| Ipratropium Bromide | 29 | $849 |
| Fluticasone Propionate | 47 | $620 |
| Montelukast Sodium | 39 | $402 |
| Azithromycin | 16 | $93 |
| Prednisone | 16 | $33 |
Paid to pharmacies, not to this prescriber.
Other adult health in Charleston
- Nolan SankoffCharleston$1K
- Kelsey ThorntonCharleston$336
- Kanchan ThapaCharleston$210
- Shelby HicksCharleston$173
- Lisa MalloryCharleston$138
- Caren WalkerCharleston$99
- Jean KernalMorgantown$6K
- Megan GeyerRavenswood$3K
- John ArrudaMorgantown$3K
- Michelle CooperMartinsburg$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.